Fresenius Group Overview

Financial Results

To archive

Q1/21 Results

Fresenius with good start to 2021 despite ongoing COVID-19 impact

  • Guidance for 2021 confirmed

  • Fresenius Medical Care delivers solid first quarter

  • Fresenius Kabi shows strong performance in Emerging Markets whilst headwinds continue to impact North American business

  • Helios Germany continues to be compensated by government for foregone elective treatments; Helios Spain delivers significant sales and earnings growth given recovery of treatment activity

  • Fresenius Vamed continues to suffer from COVID-19 related project delays; technical high-end service business remains robust

  • Preparation of Group-wide initiatives to improve efficiency and profitability progressing

Selected Key Figures Q1/2021

Sales

€ 8984 m

+3% 1

Q1/20: €9,135 m

EBIT 2

€ 1006 m

-6% 1

Q1/20: €1,125 m

Net Income 2, 3

€ 435 m

-2% 1

Q1/20: €465 m

Earnings per Share 2, 3

€ 0.78

-2% 1

Q1/20: €0.83

 

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Sales by business segment

 

€ in millions

 Q1/21

 Q1/20

Change

Organic
sales
growth
Currency translation effects Acqui-sitions Divesti-tures % of total sales1

Fresenius Medical Care

4,210 4,488 -6% 1% -7% 1% -1% 47%

Fresenius
Kabi

1,761 1,789 -2% 3% -6% 0% 1% 20%

Fresenius Helios

2,649 2,466 7% 4% -1% 4% 0% 29%
Fresenius Vamed 477 499 -4% -4% 0% 0% 0% 4%

Total

8,984 9,135 -2% 2% -5% 2% -1% 100 %

1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Archive